As the most common serious neurological condition in the U.S., epilepsy affects roughly 3.4 million Americans. It's what drives biopharmaceutical researchers to fight back with innovative medicines like targeted treatments that could transform the lives of patients living with the disease.
Epilepsy is a complex condition, and it will take an equally complex approach to put an end to the disease. America's biopharmaceutical companies will not be satisfied until that goal is reached.
<p>The evolution of HIV/AIDS treatment is nothing short of remarkable. In the 1980s, HIV/AIDS was an acute fatal disease. Today it is a chronic, manageable condition thanks to the commitment of biopharmaceutical researchers, health care workers and advocates.</p>READ MORE
<p><span><span><span><a><span lang="EN"><span>America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.</span></span></a></span></span></span></p>READ MORE
<p>Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?</p>READ MORE